Groups of 60 to 120 mice were given a single intraperitoneal inoculation of varying dilutions of commercially prepared and licensed bivalent (A/England and B/Mass) and monovalent (A/Aichi or B/Hong Kong) inactivated influenza vaccines, and their antibody responses at 14 days were quantitated by hemagglutination inhibition tests. Split-product vaccines prepared by the treatment of A/England, B/Mass, and B/Hong Kong whole virus with Tween-80 and either tributylphosphate or ether produced significantly lower mean antibody titers than did equivalent whole-virus preparations. The rates of seroconversion ( <1:8 to >1:8) at the various dilutions tested were also significantly reduced when these split-product vaccines were given. When the antigen content of all vaccines was quantitated by the chick cell agglutination test, between 10 and 100 times more split-product antigen than whole-virus antigen was required to produce seroconversion in 50% of the mice tested. Differences between splitproduct and whole-virus A/Aichi vaccines were less marked. These data point out the need to consider factors other than hemagglutinin content alone in determining the immunogenicity of inactivated influenza vaccines.
Influenza virus infection continues to be a major cause of morbidity in the United States and is the only infectious disease that regularly produces significant excess mortality (34) in spite of the long-standing availability and annual use of 15 to 25 million doses of an effective vaccine. Although the cause of this apparent paradox has in part been related to inadequate utilization of the vaccine in high-risk individuals (34) , concern over possible variations in the potency and efficacy of influenza vaccines has prompted us to re-examine the relationship between the laboratory and clinical indexes of the protective capacity of modern, highly purified, and commercially available influenza vaccines. The following report describes the results of the first of a series of studies undertaken to investigate various in vitro and in vivo parameters of the potency of these vaccines.
Because influenza virus vaccine, unlike most other contemporary viral vaccines, is an inactivated product, indirect methods of potency quantitation must be used. Currently, the potency of these vaccines is measured by the chick cell agglutination (CCA) test (20) , which directly quantitates only the hemagglutinin component of the virus. Although the test is relatively precise and reproducible when values obtained for a given vaccine are compared with a standard reference (37) , previous experiments have shown that differing egg passages (19) and various manufacturing procedures (5, 12, 23, 31, 35) might alter the relationship between the immunogenicity of influenza vaccines and their CCA content. Techniques that quantitate the immunogenic potential of vaccines in experimental animals by antigen extinction methods have therefore been suggested (27, 35) as more relevant in determining the protective capacity of inactivated vaccines. Previous two-step antigen extinction techniques involving the intranasal instillation of pooled immune serum and virus mixtures into mice (7) have been shown to be cumbersome, poorly reproducible (13, 37) , and excessively dependent on the virulence of the mouse-adapted challenge virus (26) . Since serum hemagglutination inhibiting (HI) antibodies produced in mice after parenteral inoculation of inactivated influenza vaccines are well correlated with protection from infection (10, 17) , we have evaluated the immunogenicity of a number of the commercially produced monovalent and bivalent influenza vaccines available for human use by quantitating the antibodies they produce in mice.
Two of the vaccine types tested are manufactured by treatment of the whole virus with Tween-80 and either ether or tributylphosphate (TBP) in an effort to diminish the local and systemic reactions produced by influenza vac-INFECT. IMMUNITY cines (18) . Previous experiments on the protective efficacy of experimentally produced "splitproduct" influenza vaccines in mice were somewhat contradictory (5, 12, 23) , whereas earlier experience with inactivated measles vaccines subjected to ether treatment had shown them to be, in some respects, less immunogenic than equivalent whole-virus vaccines (24, 25 Table 2 .
CCA tests. CCA determinations were performed as previously described (20) and modified (37) a Abbreviations: ZPWV, zonally purified whole virus; CPWV, chromatographically purified whole virus; TBP, tributylphosphate-treated split product; ET, ether-treated split product. 
RESULTS
Geometric mean antibody titers produced in mice by the various vaccines are shown in Fig. 1  through 4 . Split-product bivalent vaccines (E+F) formulated from A/England and B/Mass prototypes were distinctly less immunogenic at all dilutions than equivalent whole-virus vaccines (A-D) of approximately the same CCA value ( Fig. 1 and 2 ). The lowest geometric mean titer of antibody produced by a whole-virus vaccine was greater, at the 0.001 level of significance, than the highest geometric mean titer induced by a split-product vaccine at all dilutions tested. The whole-virus preparations containing the least amount of antigen as determined by CCA tests (stock vaccine diluted 10-3) induced more HI antibody than either of the split-product vaccines containing approximately 100 times as much antigen (stock vaccine diluted 10-1). When monovalent vaccines Tables I and 2 for strain, type, and CCA content of lettered vaccines. Tables 1 and 2 for strain, type, and CCA content of lettered vaccines.
prepared from B/Hong Kong prototypes are considered (Fig. 3) , the immunogenic inferiority in mice of split-product vaccines remains evident even though higher concentrations (vaccines diluted 10-1) of such vaccines produced levels of antibody equal to or slightly greater than those produced by dilutions (10-2 or 10-8) of whole-virus vaccines containing 10 to 100 times less CCA antigen. At each dilution, however, the whole-virus vaccines produced significantly more HI antibody than did the splitproduct vaccines. In the case of vaccines formulated with A/Aichi prototype strains (Fig. 4) , the least immunogenic whole-virus vaccine (C) was significantly superior only to the ethertreated (ET) split-product vaccine (F) and only at the 10-1 dilution. Addition of AlPO4 to the ET preparation markedly enhanced its immunogenicity so that it was significantly superior to the best whole-virus preparation at the 10-1 dilution and significantly superior to the ET vaccine from which it was derived at the 10-1 and 10-2 dilutions.
Seroconversion rates for the different vaccines and antigens are summarized in Fig. 5 through 8. The differences between whole and prominent when A/Aichi vaccines are considNs' F ered, but the trend in the immunogenic inferi-__ ority of split-product vaccines is made evident 10~l0-2 10-3 by the fact that two to five times more CCA DILUTION OF VACCINE antigen of the split-product vaccines was re-FIG. 6. Homotypic seroconversion rates after inocquired to produce 50% seroconversion when ulation with varying dilutions of bivalent vaccine compared with the least immunogenic whole-containing B/Mass antigen. See Tables 1 and 2 (39) . Numerous studies (1-4, 6, 14, 15, 28, 32, 33) using ET or TBP split-product vaccines in humans have been performed which indicate that their efficacy in producing sufficient serum antibodies and protection from infection appears to be approximately equal to that of whole-virus vaccines. Precise comparison between the two types of vaccines is difficult in some reports, however, because of a variety of factors, including different routes of administration (32) , the use of adjuvants (4, 14) , or the use of tests other than the CCA test to quantitate the amount of antigen given (1, 3, 6, 14) . An additional factor to consider when comparing results of studies with influenza vaccines in humans and in mice is the fact that the serological response in mice is of the primary type, whereas most previous studies comparing split-product and whole-virus influenza vaccines were performed in adults with some pre-existing experience with influenza and whose serological response would therefore be anamnestic in character. Whether subunit vaccines may be poor primary immunizing agents for seronegative individuals, who have a particular risk of influenza infection, but sufficient boosting antigens in man is equally difficult to discern, since previous studies in infants who presumably had little prior experience with influenza have shown that both ether-split (1, 15) and whole-virus (1) vaccines produced a poor serological response.
Since little is known about the precise relationship between mouse immunogenicity tests and protection from influenza infection in man (13), we are presently conducting a number of carefully controlled field studies in a variety of populations, including children, normal adults, and patients with chronic pulmonary disease, in an effort to determine whether the diminished immunogenicity of split-product vaccines in mice might also be noted in man. Results from these studies will also be correlated with other in vitro parameters of antigen quantitation including protein determinations, particle counts by electron microscopy, and polyacrylamide gel electrophoresis in order to find the most reproducible and reliable laboratory test of inactivated influenza vaccine potency.
